Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels - Université de La Réunion Access content directly
Journal Articles Immunologic Research Year : 2022

Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels

Abstract

No abstract available

Domains

Immunology

Dates and versions

hal-04104444 , version 1 (24-05-2023)

Identifiers

Cite

Anthony Dobi, Arthur Dubernet, Mahary Lalarizo Rakoto, Anne-Laure Sandenon Seteyen, Damien Vagner, et al.. Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels. Immunologic Research, 2022, 70 (5), pp.714-719. ⟨10.1007/s12026-022-09269-w⟩. ⟨hal-04104444⟩
29 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More